(Reuters) — Endo International Plc (ENDP.O) said it would buy Par Pharmaceutical Holdings Inc from private equity firm TPG Capital for about $8 billion, including debt, to become a top-five global generic drugmaker.
Dublin-based Endo’s shares rose 3 percent to $88.05 in light premarket trading on Monday.
Endo’s offer consists of about 18 million shares and $6.50 billion in cash, the company said.
Par Pharmaceutical was acquired by TPG Capital for $1.9 billion in 2012 following pressure from activist firm Relational Investors LLC to sell itself.
The company, which filed with U.S. regulators in March for an initial public offering of common stock, had debt of $2.35 billion as of March 31.
Par operates through its generics division, Par Pharmaceutical, and its proprietary products division, Strativa Pharmaceuticals.
Endo said it had secured financing from Deutsche Bank and Barclays to fund the cash consideration.
Barclays, Deutsche Bank and Houlihan Lokey are Endo’s financial advisers while JP Morgan is financial adviser to Par.
Skadden, Arps, Slate, Meagher & Flom LLP is Endo’s legal adviser and Ropes & Gray LLP is Par’s legal adviser.